Browsing by title
Now showing items 4061-4080 of 4758
-
T cell-rich lymphoid infiltrates with large B cells: a review of key entities and diagnostic approach.
(2017-03)Accurate diagnostic interpretation of a lymphoid population composed predominantly of small T cells, together with smaller numbers of large B cells, with or without a nodular architecture, is a common problem faced by the ... -
T(11;18)(q21;q21) is associated with advanced mucosa-associated lymphoid tissue lymphorna that expresses nuclear BCL10
(2001-08-15)The development of gastric mucosa-associated lymphoid tissue (MALT) lymphoma is a multistep process and can be clinico-pathologically divided into Helicobacter pylori-associated gastritis, low-grade tumors, and high-grade ... -
t(2;5) associated with a histiocytic-monocytic neoplasm
(2001-04)We describe a patient with a neoplasm derived from the histiocytic-monocytic lineage associated with t(2:5) detected by FISH. The patient presented with bone marrow involvement, no organomegaly and subsequently developed ... -
T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
(2017-09)Background Patients with metastatic sarcomas have poor outcomes and although the disease may be amenable to immunotherapies, information regarding the immunologic profiles of soft tissue sarcoma (STS) subtypes is limited.Methods ... -
T-cell large granular lymphocyte leukemia - A report on the treatment of 29 patients and a review of the literature
(2006-08-01)BACKGROUND. To the authors’ knowledge, there is no standard treatment for patients with T-cell large granular lymphocyte (LGL) leukemia. Available data are limited by patient numbers and coexisting pathologies. METHODS. ... -
T-cell Prolymphocytic Leukemia.
(2017-04)T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive T-cell malignancy. T-PLL can be distinguished from other lymphoid diseases by the evaluation and integration of clinical features, morphology, immunophenotyping, ... -
T-DM1 in the Neo-Adjuvant Treatment of HER2-Positive Breast Cancer: Impact of the KRISTINE (TRIO-021) Trial
(Bentham Science Publishers Ltd., 2017-11-08) -
T2-Weighted 4D Magnetic Resonance Imaging for Application in Magnetic Resonance-Guided Radiotherapy Treatment Planning.
(2017-10)Objectives The aim of this study was to develop and verify a method to obtain good temporal resolution T2-weighted 4-dimensional (4D-T2w) magnetic resonance imaging (MRI) by using motion information from T1-weighted 4D ... -
T<sub>2</sub>-adjusted computed diffusion-weighted imaging: A novel method to enhance tumour visualisation.
(2016-12)Purpose To introduce T 2 -adjusted computed DWI (T 2 -cDWI), a method that provides synthetic images at arbitrary b-values and echo times (TEs) that improve tissue contrast by removing or increasing T 2 contrast in ... -
Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer.
Insertion mutations in exon 20 (Ex20ins) of the epidermal growth factor receptor ( EGFR ) gene are the largest class of EGFR mutations in non-small cell lung cancer (NSCLC) for which there are currently no approved targeted ... -
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
Background In the Suppression of Ovarian Function Trial (SOFT) and the Tamoxifen and Exemestane Trial (TEXT), the 5-year rates of recurrence of breast cancer were significantly lower among premenopausal women who received ... -
Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study.
Purpose The prognosis for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is poor, and only a minority of patients benefit from checkpoint immunotherapy. Talimogene laherparepvec ... -
Tamoxifen-related porphyria cutanea tarda
(2002)Tamoxifen-related porphyria cutanea tarda. We report a case of porphyria cutanea tarda (PCT) in a patient with breast cancer following adjuvant tamoxifen. Cessation of tamoxifen resulted in a prompt decline in urinary ... -
Tankyrase Requires SAM Domain-Dependent Polymerization to Support Wnt-β-Catenin Signaling.
(2016-08)The poly(ADP-ribose) polymerase (PARP) Tankyrase (TNKS and TNKS2) is paramount to Wnt-β-catenin signaling and a promising therapeutic target in Wnt-dependent cancers. The pool of active β-catenin is normally limited by ... -
Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre.
(2018-10-15)Background Greater understanding of the molecular classification of breast cancer has permitted the development of rational drug design strategies. In a phase I clinical trial setting, molecular profiling with next-generation ... -
Targeted agents in cancer therapy
(2008)Significant progress has been made over recent years in understanding the molecular and cellular processes involved in cancer biology. The identification of several molecular targets which are involved in cancer development ... -
Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review.
(2018-12)Importance Targeted alpha therapy attempts to deliver systemic radiation selectively to cancer cells while minimizing systemic toxic effects and may lead to additional treatment options for many cancer types.Observations ... -
Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification.
(2019-09)Objectives To develop a focused panel of somatic mutations (SMs) present in the majority of urothelial bladder cancers (UBCs), to investigate the diagnostic and prognostic utility of this panel, and to compare the ...
